Bet_Noire
- Embecta (NASDAQ:EMBC) has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes.
- The system includes a tubeless patch pump with a 300-unit insulin reservoir and a locked-down controller with Bluetooth technology.
- Embecta said the 300-unit reservoir design is aimed at accommodating the needs of type 2 diabetics who have higher daily insulin needs, according to a statement.
- Embecta added it is also working on a closed-loop patch pump device that includes an insulin-dosing algorithm.
- Wells Fargo pointed out that Insulet (PODD) recently received FDA clearance for its Omnipod 5 insulin delivery system for type 2 diabetes, while Tandem Diabetes Care (TNDM) expects to submit an application to get its device approved for type 2 diabetes “shortly.”
- The investment bank noted that Insulet’s Omnipod 5 only has a 200-unit reservoir versus Embecta’s 300-unit.
- “This is important because people with type 2 tend to use more insulin,” the bank added.
